pISSN 1226-6051
eISSN 2508-786X

Fig. 2.

Download original image
Fig. 2. A survey on cases exempted from mandatory submission of DSUR. A: Generic Drugs, B: New Combination Drugs (all ingredients licensed), C: Drugs for Investigator’s initiated trial (IIT) D: Licensed drugs which get IND approval for formulation change, E: Licensed drugs which get IND approval for the addition of efficacy·effectiveness), F: Licensed drugs which get IND approval for new route of administration, addition or change of usage·dosage, G: Bio-similar, H: The Others
Korean J Clin Pharm 2021;31:53-60 https://doi.org/10.24304/kjcp.2021.31.1.53
© 2021 Korean J Clin Pharm